GENOMICS & LIFE SCIENCES
DISRUPTIVE GROWTH
NUTRICEUTICALS
AED CATEGORY
PLASTICS
DIGITAL DISPLAYS
SMART GLASS
DISASTER MANAGEMENT
ADVANCED SCIENCES
CLIMATE
FEATURED
Technology · Life Sciences
Fortune 500 technology company
$1.4B in new revenue. $125M invested. New CVC capability built from the ground up.
Vaxa built a bottom-up market model from the drug discovery process itself — revealing an opportunity no one had properly sized. One pitch to three companies. One moved first within six months. Corporate ventures invested over $25M in life sciences VC funds.
— CLIENT OUTCOMES
A market entry built on what you have — and designed for what you don't.
01
Clarity on which assets actually travel
A structured, honest assessment of which existing capabilities, relationships, technologies, and channels are genuinely deployable in the new market — and which only appear to be. Most organizations overestimate both. This assessment changes the entry design before capital is committed.
Entry designed on actual transferable assets, not assumed ones
02
A gap-filling strategy that uses the right mechanism
What cannot be transferred must be partnered, built, or acquired. Vaxa determines which mechanism is right for each gap — and in what order. The wrong mechanism for the wrong gap at the wrong time is the second most common failure point in new market entry.
Each gap addressed through the right partner, build, or acquisition path
03
A phased entry with defined triggers
New market entry that tries to do everything at once rarely survives first contact. Vaxa designs the phases — what moves first, what follows, and what the commercial and competitive triggers are before each step is taken. The entry is a sequence, not a single bet.
Entry sequenced in phases with clear triggers between each
04
The first customers before the entry scales
The specific organizations most likely to convert first, the commercial model that makes the first transaction possible, and the approach to reach them before the broader entry begins. Early customers in a new market are not a scale problem — they are a design problem.
First customer pipeline defined and sequenced before execution starts
— The Work Spans
Industries, geographies, and stages.
TECHNOLOGY
-
Fortune 50 enterprise software companies
-
Semiconductors and AI
-
Consumer electronics companies
-
Enterprise storage and infrastructure
Life Sciences & Health
-
Global medical device manufacturers
-
Medical wearable device companies
-
European theranostics, imaging startups
-
Global biotechnology companies
Industrials, Consumer & Public
-
Fortune 50 consumer packaged goods
-
Global automotive manufacturers
-
European telecommunications companies
-
US federal government agencies
Stay ahead of what's forming. Subscribe to Vaxa Insights — our look at the critical issues and emerging opportunities facing businesses today.
Client confidentiality is non-negotiable. Names, engagement details, and outcomes are not shared without explicit permission. What is shown here reflects the character and scale of the work — not the full scope of it.
— CLIENT RESULTS
We don't just find markets.
We help build them.
At Vaxa, we have a passion for seeing things differently — for sensing what's forming before it's visible to anyone else. We work with clients who share that instinct, and together we turn what others overlook into markets, categories, and top-line growth that didn't exist before.